Latest News
Catalent Acquires 60,000-SF Japanese Facility to Support Clinical Studies with GMP Manufacturing and Distribution Hub
Friday 22 May 2020

New Jersey, US-based clinical supply services company Catalent has agreed to acquire a 60,000-square-foot clinical packaging facility in Japan from Teva-Takeda Pharmaceuticals, to expand capacity to meet the growing demand in biologics and cell and gene therapy studies, the company said.

Financial details of the deal, which is expected to close on July 1, 2020, have not been disclosed.

The facility will be the largest in the company's Asia Pacific clinical supply network.

The new facility will offer customers access to Catalent's FastChain demand-led supply services, primary and secondary packaging capabilities, a range of temperature options for storage and distribution, as well as clinical returns and destruction services.

It will operate in partnership with Catalent's existing Japanese clinical supply facility at Kakegawa, serving both local customers as well as global biotech and pharmaceutical companies.

Catalent Clinical Supply Services offers clinical supply services, with comprehensive and flexible solutions for small molecules, biologics, and cell and gene therapies and integrated solutions to accelerate speed to clinic.

Catalent offers a full range services including clinical supply management, comprehensive packaging solutions, comparator sourcing, cold chain storage and global distribution and specialised supply chain services including direct-to-patient and demand-led supply.

Catalent is a provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products.
Date Published: 22/05/2020